ASH 2024 discussions shine spotlight on advances in haemophilia treatments
At the American Society of Hematology (ASH) Annual Meeting 2024, physicians looked back at the progress made in the prophylactic and curative care of hemophilia since the approval of Roche’s Hemlibra (emicizumab). The weekly or monthly subcutaneous …